Individualised follow-up for head and neck cancer-design of a prospective cohort study to assess its feasibility
Publication year
2022Source
BMJ Open, 12, 12, (2022), article e068750ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Otorhinolaryngology
Radiation Oncology
Haematology
IQ Healthcare
Journal title
BMJ Open
Volume
vol. 12
Issue
iss. 12
Subject
Radboudumc 15: Urological cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences; Haematology - Radboud University Medical Center; Otorhinolaryngology - Radboud University Medical Center; Radiation Oncology - Radboud University Medical CenterAbstract
INTRODUCTION: It is a common practice for many cancer types to monitor patients after treatment to detect new disease manifestations early. For head and neck cancer (HNC), however, long-term routine follow-up is up for debate for several reasons. The benefits of prolonged routine follow-up on survival have not been proven. Also, cancer follow-up is putting increasing pressure on healthcare resources due to rising incidence and survival rates. Therefore, this study investigates a novel follow-up approach among HNC patients, giving them the opportunity to choose their own follow-up programme. METHODS AND ANALYSIS: HNC patients are offered a decision-aided choice between standardised or individualised follow-up after 1.5 years of uncomplicated guideline-prescribed follow-up. Standardised follow-up entails continuing the 5-year guideline-prescribed schedule. Individualised follow-up means the patient only attends the outpatient clinic on their own initiative in case of physical symptoms or supportive care needs. Patients are educated on self-examination and when a control visit is necessary. The primary outcome measure is the feasibility of offering patients this choice. Secondary outcome measures are quality of life, costs, productivity loss and detection of new disease. ETHICS AND DISSEMINATION: We believe that it is essential to let patients determine their follow-up programme based on their own values and preferences. If this choice is feasible, it can be implemented and investigated in other HNC care centres. TRIAL REGISTRATION NUMBER: NCT05386225.
This item appears in the following Collection(s)
- Academic publications [243984]
- Electronic publications [130695]
- Faculty of Medical Sciences [92811]
- Open Access publications [104970]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.